RIGEL PHARMACEUTICALS INC (RIGL) — insider trading
Health Care · NASDAQ
RIGEL PHARMACEUTICALS INC (RIGL) has 37 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 37 (latest 2026-09-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion (derivative) | 1,286 | — | $0 | Form 4 |
| 2026-09-02 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion (derivative) | 2,000 | — | $0 | Form 4 |
| 2026-09-02 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion (derivative) | 620 | — | $0 | Form 4 |
| 2026-09-02 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion (derivative) | 694 | — | $0 | Form 4 |
| 2026-09-02 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion | 1,286 | $24.20 | $31.1K | Form 4 |
| 2026-09-02 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion | 2,000 | $24.20 | $48.4K | Form 4 |
| 2026-09-02 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion | 620 | $18.70 | $11.6K | Form 4 |
| 2026-09-02 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion | 694 | $12.70 | $8.8K | Form 4 |
| 2026-09-01 | Furey Raymond J. | Officer (EVP, GC, CCO & Corp Sec) | Shares withheld for taxes / exercise cost | 877 | $47.50 | $41.7K | Form 4 |
| 2026-09-01 | RODRIGUEZ RAUL R | Director, Officer (CEO, President) | Shares withheld for taxes / exercise cost | 2,424 | $47.50 | $115.1K | Form 4 |
| 2026-09-01 | Santos David A | Officer (EVP, Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 874 | $47.50 | $41.5K | Form 4 |
| 2026-09-01 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Shares withheld for taxes / exercise cost | 928 | $47.50 | $44.1K | Form 4 |
| 2026-07-08 | HANNAH ALISON L. | Officer (EVP, Chief Medical Officer) | Grant / award / vesting | 24,400 | — | $0 | Form 4 |
| 2026-06-22 | Ali-Jackson Kamil | Director | Open-market sale | 2,500 | $35.00 | $87.5K | Form 4 |
| 2026-06-17 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Grant / award / vesting (derivative) | 7,394 | — | $0 | Form 4 |
| 2026-06-17 | Santos David A | Officer (EVP, Chief Commercial Officer) | Grant / award / vesting (derivative) | 7,394 | — | $0 | Form 4 |
| 2026-06-17 | RODRIGUEZ RAUL R | Director, Officer (CEO, President) | Grant / award / vesting (derivative) | 31,700 | — | $0 | Form 4 |
| 2026-06-17 | Rojkjaer Lisa | Officer (EVP, Chief Medical Officer) | Grant / award / vesting (derivative) | 7,394 | — | $0 | Form 4 |
| 2026-06-17 | Rojkjaer Lisa | Officer (EVP, Chief Medical Officer) | Grant / award / vesting (derivative) | 9,375 | — | $0 | Form 4 |
| 2026-06-17 | Furey Raymond J. | Officer (EVP, GC, CCO & Corp Sec) | Grant / award / vesting (derivative) | 7,394 | — | $0 | Form 4 |
| 2026-06-01 | Furey Raymond J. | Officer (EVP, GC, CCO & Corp Sec) | Shares withheld for taxes / exercise cost | 877 | $29.86 | $26.2K | Form 4 |
| 2026-06-01 | RODRIGUEZ RAUL R | Director, Officer (CEO, President) | Shares withheld for taxes / exercise cost | 2,424 | $29.86 | $72.4K | Form 4 |
| 2026-06-01 | Rojkjaer Lisa | Officer (EVP, Chief Medical Officer) | Shares withheld for taxes / exercise cost | 850 | $29.86 | $25.4K | Form 4 |
| 2026-06-01 | Santos David A | Officer (EVP, Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 874 | $29.86 | $26.1K | Form 4 |
| 2026-06-01 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion (derivative) | 2,181 | — | $0 | Form 4 |
| 2026-06-01 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion (derivative) | 1,200 | — | $0 | Form 4 |
| 2026-06-01 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Shares withheld for taxes / exercise cost | 928 | $29.86 | $27.7K | Form 4 |
| 2026-06-01 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion | 2,181 | $12.70 | $27.7K | Form 4 |
| 2026-06-01 | Schorno Dean L | Officer (EVP & Chief Financial Officer) | Option exercise / conversion | 1,200 | $18.70 | $22.4K | Form 4 |
| 2026-05-26 | Ali-Jackson Kamil | Director | Open-market sale | 2,500 | $29.17 | $72.9K | Form 4 |
| 2026-05-15 | Ali-Jackson Kamil | Director | Grant / award / vesting | 5,750 | — | $0 | Form 4 |
| 2026-05-15 | Frohlich Mark W | Director | Grant / award / vesting | 5,750 | — | $0 | Form 4 |
| 2026-05-15 | HANNAH ALISON L. | Director | Grant / award / vesting | 5,750 | — | $0 | Form 4 |
| 2026-05-15 | LAPOINTE ANTHONY GREGG | Director | Grant / award / vesting | 5,750 | — | $0 | Form 4 |
| 2026-05-15 | MILLER MICHAEL PATRICK | Director | Grant / award / vesting | 5,750 | — | $0 | Form 4 |
| 2026-05-15 | MOOS WALTER H | Director | Grant / award / vesting | 5,750 | — | $0 | Form 4 |
| 2026-05-15 | Wasman Jane | Director | Grant / award / vesting | 5,750 | — | $0 | Form 4 |
Ask the chat about RIGL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: RIGEL PHARMACEUTICALS INC (RIGL).
Last updated 2026-09-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.